GSK, Jemperli and european union
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...
GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will ...
In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...
The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...
The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...
J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...
The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.
Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.
Shares of GSK PLC GSK inched up 0.59% to £13.64 Thursday, on what proved to be an all-around positive trading session for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback